← SynDRA
TAZEMETOSTAT
SynDRA canonical compound SYN0038140 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx |
| Primary target(s) | EZH2 |
| Mechanism of action | histone lysine methyltransferase inhibitor |
All known targets
Mechanisms of action (all sources)
- EZH2 INHIBITOR
- Histone-lysine N-methyltransferase EZH2 inhibitor
- histone lysine methyltransferase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- EHMT2
- ABCB11
- HTR2B
- MAPK1
- MAOA
- KDR
- KCNH2
- HTR3A
- HTR2C
- HTR2A
- FGFR2
- HTR1A
- HRH3
- HRH1
- HDAC6
- GSK3B
- MC3R
- MLNR
- NR1I2
- NR3C1
- OPRD1
- OPRM1
- PDE3A
- PDE4D
- PGR
- PPARG
- PTGS2
- SCN5A
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- TBXA2R
- GHSR
- FAP
- ABL1
- ESR1
- ACHE
- ADORA1
- ADORA2A
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- AEBP2
- CP2C9
- CP2D6
- CP3A7
- KSYK
- RBBP4
- SUZ12
- SYK
Drug classes
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors
- Methyltransferase Inhibitor
- Methyltransferase Inhibitors
- Multidrug and Toxin Extrusion Transporter 2 K Inhibitors
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- TAZVERIK
- Tazverik
- tazemetostat hydrobromide
- tazverik
- EPZ-6438
- EZ438
- CT-EPZ438EPZ-6438EPZ6438A-1623E-7438E7438
- E-7438
- E7438
- EPZ6438
- TAZEMETOSTAT (EPZ-6438)
- EPZ 6438
- UNII-Q40W93WPE1
- Q40W93WPE1
- Tazemetostat [INN]
- E 7438
- Tazemetostat [USAN]
- Tazemetostat(EPZ-6438)
- Tazemetostat (EPZ-6438)
- MFCD24849415
- TAZEMETOSTAT [MI]
- Tazemetostat (USAN/INN)
- Tazemetostat [USAN:INN]
- TAZEMETOSTAT [WHO-DD]
- GTPL7011
- CHEMBL3414621
- SCHEMBL13276848
- SCHEMBL19325409
- SCHEMBL22210809
- EX-A509
- DTXSID201025831
- HMS3653O07
- HMS3747A09
- BCP07409
- NSC777109
- NSC791066
- s7128
- AKOS026750211
Reported adverse events
- Abdominal pain
- Alopecia
- Constipation
- Cough
- Fatigue
- Headache
- Infection
- Lower respiratory tract infection
- Musculoskeletal pain
- Nausea
- Pain
- Pyrexia
Look up TAZEMETOSTAT in the interactive SynDRA portal →